Table 3.
Summary of variables
| Variable | No. of patients | % | |
|---|---|---|---|
| Gender | |||
| Male | 25 | 71 | |
| Female | 10 | 29 | |
| Primary tumor | |||
| Colon | 26 | 74 | |
| Rectum | 9 | 26 | |
| Dukes' stage | |||
| B | 13 | 37 | |
| C | 22 | 63 | |
| Synchronous | |||
| Yes | 15 | 43 | |
| No | 20 | 57 | |
| No. of pathological lesions | |||
| 1 | 12 | 34 | |
| 2–4 | 18 | 51 | |
| >4 | 5 | 14 | |
| DFI | |||
| <12 months | 20 | 55 | |
| ≥12 months | 15 | 45 | |
| Margins | |||
| >1 cm | 18 | 51 | |
| <1 cm | 17 | 48 | |
| Positive margins (≤0.1 cm) | 4 | 11 | |
| Previous chemotherapy | |||
| Yes | 25 | 71 | |
| No | 10 | 29 | |
| Previous CPT-11, yes | 12 | 34 | |
| Age, years | |||
| Median | 58 | ||
| Range | 41–75 | ||
| Preoperative CEA | |||
| >30 ng/ml | 4 | 11 | |
| Postoperative CEA | |||
| >5 ng/ml | 4 | 11 | |
| Size of metastatic lesion | |||
| ≥5 cm | 7 | 20 | |
| Metastatic lesions | |||
| Bordering vessels, yes | 16 | 46 | |
| ≥2 vessels, yes | 2 | 6 | |
| Central, yes | 4 | 11 | |
| Bordering vena cava, yes | 2 | 6 | |
| Bilobar | 14 | 40 | |
| Above normal | |||
| Preoperative CEA | 19 | 54 | |
| Postoperative CEA | 4 | 11 | |
| LDH | 0 | 0 | |
| Alkaline phosphatase | 22 | 63 | |
| Bilirubin | 5 | 14 | |
| AST | 3 | 9 |
DFI, disease free interval; CEA, carcinoembryonic antigen; LDH, lactic dehydrogenase; AST, aspartate aminotransferase.